These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34337483)

  • 1. High Serine-arginine Protein Kinase 1 Expression with PTEN Loss Defines Aggressive Phenotype of Prostate Cancer Associated with Lethal Outcome and Decreased Overall Survival.
    Abou-Ouf H; Assem H; Ghosh S; Karnes RJ; Stoletov K; Palanisamy N; Lewis JD; Bismar TA
    Eur Urol Open Sci; 2021 Jan; 23():1-8. PubMed ID: 34337483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased ATM Protein Expression Is Substantiated with PTEN Loss in Defining Aggressive Phenotype of Prostate Cancer Associated with Lethal Disease.
    Walker SR; Abdelsalam R; Ghosh S; Livingstone J; Palanisamy N; Boutros PC; Yip SM; Lees-Miller SP; Bismar TA
    Eur Urol Open Sci; 2021 Jul; 29():93-101. PubMed ID: 34337539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.
    Abou-Ouf H; Ghosh S; Box A; Palanisamy N; Bismar TA
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1751-1759. PubMed ID: 31129769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification.
    Bismar TA; Hegazy S; Feng Z; Yu D; Donnelly B; Palanisamy N; Trock BJ
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2117-2125. PubMed ID: 30101374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.
    Huang KC; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
    Cancer Biol Ther; 2014 Sep; 15(9):1120-8. PubMed ID: 24972028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Association between Cyclin Dependent Kinase 2 Associated Protein 1 (CDK2AP1) and Molecular Subtypes of Lethal Prostate Cancer.
    Gamallat Y; Bakker A; Khosh Kish E; Choudhry M; Walker S; Aldakheel S; Seyedi S; Huang KC; Ghosh S; Gotto G; Bismar TA
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
    Yang DD; Mahal BA; Muralidhar V; Martin NE; Orio PF; Mouw KW; King MT; Choueiri TK; Trinh QD; Hoffman KE; Spratt DE; Feng FY; Nguyen PL
    Eur Urol; 2019 Jan; 75(1):35-41. PubMed ID: 30554605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
    Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
    Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.
    Kishan AU; Wang X; Seiferheld W; Collette L; Sandler KA; Sandler HM; Bolla M; Maingon P; De Reijke T; Hanks GE; Nickols NG; Rettig M; Drakaki A; Reiter RE; Spratt DE; Kupelian PA; Steinberg ML; King CR
    JAMA Oncol; 2019 Jan; 5(1):91-96. PubMed ID: 30326032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
    Ahearn TU; Pettersson A; Ebot EM; Gerke T; Graff RE; Morais CL; Hicks JL; Wilson KM; Rider JR; Sesso HD; Fiorentino M; Flavin R; Finn S; Giovannucci EL; Loda M; Stampfer MJ; De Marzo AM; Mucci LA; Lotan TL
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26615022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.
    Lokman U; Erickson AM; Vasarainen H; Rannikko AS; Mirtti T
    Eur Urol Focus; 2018 Dec; 4(6):867-873. PubMed ID: 28753869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.
    Abdelsalam RA; Khalifeh I; Box A; Kalantarian M; Ghosh S; Abou-Ouf H; Lotfi T; Shahait M; Palanisamy N; Bismar TA
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1701-1709. PubMed ID: 32350606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome.
    Bismar TA; Alshalalfa M; Petersen LF; Teng LH; Gerke T; Bakkar A; Al-Mami A; Liu S; Dolph M; Mucci LA; Alhajj R
    BJU Int; 2014 Feb; 113(2):309-19. PubMed ID: 24006850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality.
    Bismar TA; Dolph M; Teng LH; Liu S; Donnelly B
    Eur J Cancer; 2012 Mar; 48(4):538-46. PubMed ID: 22300588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis.
    Al Bashir S; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
    J Hematol Oncol; 2014 Mar; 7():21. PubMed ID: 24606912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.
    Huang KC; Bégin LR; Palanisamy N; Donnelly B; Bismar TA
    Urol Oncol; 2016 May; 34(5):235.e1-10. PubMed ID: 26725250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.
    Lotan TL; Wei W; Morais CL; Hawley ST; Fazli L; Hurtado-Coll A; Troyer D; McKenney JK; Simko J; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Feng Z; Brooks JD
    Eur Urol Focus; 2016 Jun; 2(2):180-188. PubMed ID: 27617307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serrate RNA Effector Molecule (SRRT) Is Associated with Prostate Cancer Progression and Is a Predictor of Poor Prognosis in Lethal Prostate Cancer.
    Gamallat Y; Choudhry M; Li Q; Rokne JG; Alhajj R; Abdelsalam R; Ghosh S; Arbet J; Boutros PC; Bismar TA
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated LAMTOR4 Expression Is Associated with Lethal Prostate Cancer and Its Knockdown Decreases Cell Proliferation, Invasion, and Migration In Vitro.
    Gamallat Y; Alwazan H; Turko R; Dang V; Seyedi S; Ghosh S; Bismar TA
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.